GVHD-specific survival (GSS) has been investigated as a potential study end point to describe the clinical course and outcome of chronic GVHD (cGVHD). However, reaching this end point requires a long observation time. We hypothesized that the time to the first flare-up (FFU) of cGVHD (TTF) can be an alternative statistical end point to GSS. This retrospective study included 96 patients with a diagnosis of cGVHD from a cohort of 119 patients with a prior history of acute GVHD. The median TTF was 73 days after the diagnosis of cGVHD. The 2-year cumulative incidences of first, second and third episodes of flare-up (FU) during courses of cGVHD were estimated as 69.5, 46.4 and 22.1%. Those patients who did not have an episode of FU of cGVHD had 96.0% of 2-years GSS rate, while those with 1 and X2 episodes had 50.8 and 46.8%, respectively (P ¼ 0.001). Shorter TTF was associated with poor GSS and decreased overall survival. The shorter TTF during the course of cGVHD was significantly associated with extensive cGVHD (P ¼ 0.002), Hopkins' risk category (P ¼ 0.022) and progressive-type cGVHD (Po0.001) in multivariate analysis. We propose that TTF can be an alternative end point to GSS in cGVHD trials.
Introduction
Several prognostic systems have already been evaluated and applied to predict the prognosis of patients experiencing chronic GVHD (cGVHD), including new guidelines for global assessment of cGVHD severity. [1] [2] [3] [4] [5] Recently, new end points have been introduced to evaluate the prognosis of patients with cGVHD, such as GVHD-specific survival (GSS) and the duration of systemic immunosuppressive treatment. 4, 6 In the concept of GSS, only GVHD-related deaths are counted as end events. Deaths due to disease progression are excluded. Accordingly, GSS reflects outcomes affected by GVHD alone more precisely than overall survival (OS) does, and would therefore be a fairer measure of a GVHD-modifying therapy. However, to reach the end point of the observation, a relatively lone period of followup is needed.
Recently, a chemotherapy trial for colorectal cancer suggested that the substitution of 3-year disease-free survival (or time-to-progression) for 5-year OS could reduce the study time and, therefore, reduce the labor required to evaluate a new regimen. 7 This approach was derived from the finding that the event of progression or relapse precedes the event of death in cancer patients. With this approach, the duration of a clinical trial evaluating the efficacy of a regimen can be substantially shortened. If one incorporates this concept into the course of cGVHD, the first episode of flare-up (FU) of GVHD during systemic immunosuppression for cGVHD can be viewed as the preceding event before GVHD-related mortalities occur.
Accordingly, building on a series of previous investigations, 8, 9 the current study assessed the clinical course of 96 patients with progressive or quiescent-type cGVHD derived from a cohort of 119 patients who experienced acute GVHD. We hypothesized that the time to the first FU (FFU) of cGVHD (TTF) can be used as an alternative prognostic end point to GSS. We evaluated this hypothesis in this retrospective cohort study.
Patients and methods

Patients' characteristics
The characteristics and transplant outcomes of the current cohort are summarized in Table 1 . From a cohort of consecutive patients with acute GVHD who received systemic immunosuppressive treatment (n ¼ 141), 119 cases were evaluated for cGVHD, of whom 96 patients were diagnosed with cGVHD (81%) and included in the present analysis. The transplant protocols, and supportive care maneuvers peri-transplant were conducted as previously described. 10, 11 Among these cases (n ¼ 96), 51 consecutive patients underwent allogeneic SCT at the Asan Medical Center in Seoul, Korea, between January 1996 and August 2003, and 45 consecutive patients were transplanted at Kyungpook National University Hospital in Daegu, Korea, between September 1998 and January 2004. The clinical and laboratory data for the patients were retrieved from the allogeneic SCT database and medical records. Tapering of GVHD prophylaxis such as cyclosporine (CSA, n ¼ 96) started 3 months post transplant for HLAidentical sibling SCT or 6 months post-SCT for unrelated or mismatched donor transplants or patients with aplastic anemia, unless the recipient required systemic immunosuppressive treatment for GVHD.
Treatment for GVHD
The frontline treatment for the treatment of acute GVHD was prednisone (1-2 mg/kg/day). The failure rate of steroid treatment for acute GVHD was 47% (45/96 patients). When a patient failed to respond to steroids, second-line therapy with mycophenolate mofetil (MMF), FK506, thalidomide or ATG was initiated as described previously. 10, 11 The frontline treatment for cGVHD was prednisone (1-2 mg/kg/day; n ¼ 48, 50%) or the reintroduction of CSA to the therapeutic dose (n ¼ 6, 6%), both (n ¼ 37, 38%) or other agents (n ¼ 5, 5%). If further immunosuppressive treatment was needed to control GVHD, a salvage regimen was introduced according to the patient's clinical manifestations or toxicity profiles. This included the use of therapeutic doses of CSA, FK506, MMF or combination therapy. The tapering of the immunosuppressive agent(s) was carried out biweekly by 10-25% dose reduction in the case of the FFU episode, or every 4-8 weeks by 10-15% dose reduction in the case of the second or subsequent FU episodes according to the patients' symptom(s), signs(s) and/or laboratory findings or pulmonary function test(s) after stabilization of the FU episode.
Definitions of terms
The day of the stem cell infusion was defined as day 0. A diagnosis of acute GVHD was determined by consensus criteria, 8, 12 while a diagnosis of cGVHD was made based on the day of onset after SCT using the Seattle criteria.
1,2 If GVHD occurred beyond day 100, it was considered to be cGVHD in the current study. The day of onset of overall or extensive cGVHD was defined as the date of the commencement of clinical sign(s) of cGVHD and/or the date of histological confirmation. The severity of the cGVHD was evaluated at the time of cGVHD diagnosis using three prognostic systems: the Seattle criteria, 1 Hopkins' risk category 4, 13 and severity of cGVHD system. 3 GSS was defined as the interval from the onset of cGVHD to death due to GVHD itself or GVHD-related complications. 4, 6 Deaths due to events that were not related to cGVHD were censored at the time of the event, including relapse, organ failure not related to cGVHD or accidental death.
The definitions of FU during the course of cGVHD included: (1) a situation requiring a higher dose of systemic immunosuppression (that is prednisone over 1-2 mg/kg/ day, therapeutic dosage of CSA with blood CSA level between 200 and 400 mg/l or a reinstitution of other immunosuppressive agents at the dose that had been given at the time of previous FU) due to a FU of GVHD-related symptom(s), sign(s) or laboratory finding(s); (2) a situation requiring a new line of systemic immunosuppressive therapy for the same reasons as above or (3) recurrence of cGVHD after discontinuation of immunosuppression. The TTF was calculated from the date of onset of cGVHD treatment to the date of the FFU of cGVHD considering progression or non-relapse mortality (NRM) not associated with GVHD to be competing risks.
Statistics
The results were analyzed according to the information available as of April 2005 after Institutional Research Board approval of this retrospective analysis in each hospital. The primary objective of the current study was to estimate the TTF in the cohort. Secondary objectives included: (1) evaluation of whether or not FFU was an event preceding GVHD-specific mortality and (2) identification of the risk factors for FFU in the cohort. The probability of GSS was estimated and plotted using the Kaplan-Meier method, while the cumulative incidence of the first FU of cGVHD (FFU), cGVHD and withdrawal of immunosuppression after resolution of cGVHD were calculated considering progression or NRM not associated with GVHD as competing risks for events of interest. The GSS among patients with none, one or multiple episodes of FU of GVHD was compared by a log-rank test.
To identify the risk factors for the FFU of cGVHD, univariate analyses were performed for TTF using log-rank test, including established prognostic factors for GSS such as prognostic systems or components of each prognostic system. Owing to the absence of a validating data set, we used the multivariate analysis of risk factor(s) for TTF to evaluate the association between TTF and GSS. Multivariate survival analysis using Cox's proportional hazard model was performed using forward conditional selection procedures.
To evaluate the association of TTF with GSS and OS, multivariate analyses using a time-dependent version of Cox's proportional hazard model were performed using forward stepwise procedures. In multivariate analyses, two models were generated based on either prognostic systems for cGVHD or components of the prognostic systems. Model 1 was derived from three prognostic systems (the Seattle criteria, Hopkins' risk category and severity of cGVHD criteria), while model 2 was derived from the components of these prognostic systems, including progressive-type onset, thrombocytopenia, extensive skin involvement, poor performance status, weight loss and diarrhea at diagnosis of cGVHD. As all the variables in models 1 and 2 were statistically significant at a P-value of less than 0.1, all variables were included into the final model of multivariate analysis. The hazard ratio (HR) and 95% confidence interval (CI) were also estimated with a predetermined risk of 1.0. A cutoff P-value of 0.05 was adopted for all the statistical analyses. The statistical data were obtained using an SPSS software (SPSS version 13.0, Chicago, IL, USA) and R package, version 2.4.1 (available at http://CRAN.R-project.org).
Results
Transplantation outcomes and description of cGVHD
With a median follow-up duration for the surviving patients of 854 days (range, 403-2306 days), the median day of onset of overall and extensive cGVHD was 114 and 224 days post transplant, respectively. The cumulative incidence of overall and extensive cGVHD at 2 years was 77.3 and 56.3%, respectively. The probability of GSS and the incidence of withdrawal of immunosuppressive treatment at 2 years after diagnosis of cGVHD was 60.6 and 32.7%, respectively (Figure 1) . The clinical presentation and severity of cGVHD are summarized in Table 2 .
TTF and association with GSS or OS Among the 96 patients diagnosed with cGVHD, 69 patients (72%) had an FFU at a median of 73 days (95%CI, 84-168 days) after the diagnosis of cGVHD. Thirty-six patients (38%) had a second FU episode, and 16 of these patients (17%) experienced a third episode of FU. The 2-year cumulative incidence of a first, second and third episode of FU of cGVHD was estimated to be 69.5, 46.4 and 22.1%, respectively ( Figure 2) .
The treatment of the FFU of cGVHD in the current cohort included 39 cases (56%) requiring a higher dose of systemic immunosuppression, 26 cases (38%) requiring another line of immunosuppressive agents and four cases (6%) requiring reinitiation of systemic immunosuppression due to recurrence of cGVHD after discontinuation of immunosuppression.
When evaluating the GSS according to the number of FU episodes of cGVHD, the patients without any FU episode had a 96.0% 2 year GSS, while those with 1-and X2-FU episode(s) had 50.8 and 46.8% of 2 year GSS, respectively (P ¼ 0.001, Figure 3a) . When comparing the group with and without FU episodes of cGVHD, the GSS was significantly better for the group without any FU episodes of cGVHD (96.0 versus 48.7%, Po0.001).
The patients were divided into three groups according to the day at which the FFU was diagnosed: (1) Years from transplantation GVHD-specific survival Probability of GVHD-specific survival Figure 1 GSS and the cumulative incidence of withdrawal of systemic immunosuppressive treatment after resolution of cGVHD. cGVHD, chronic GVHD; GSS, GVHD-specific survival. Figure 3b . As shown in Table 3 , in the multivariate survival analysis to evaluate the association of TTF with GSS, the TTF as a time-dependent covariate was identified as an independent risk factor for GSS (Po0.001, HR 32.30 and 29.97 in models 1 and 2, respectively) and OS (Po0.001, HR 46.92) as compared to other clinical factors.
Risk factors for FFU episode of cGVHD
In univariate analyses to identify the risk factors for TTF, good correlation was noted between the TTF and severity of cGVHD based on the Seattle system (P ¼ 0.001), Table 2 Clinical characteristics of chronic GVHD Chronic GVHD (%), evaluated n ¼ Hopkins' risk category (Po0.001) and the severity of cGVHD criteria (P ¼ 0.002). In addition, TTF correlated well with each component of the prognostic systems: progressive type onset (Po0.001), thrombocytopenia (P ¼ 0.003), extensive skin involvement (P ¼ 0.012), weight loss (P ¼ 0.008), poor performance (P ¼ 0.001) and diarrhea (P ¼ 0.003). As shown in Table 3 , extensive cGVHD (P ¼ 0.002), Hopkins' risk category (P ¼ 0.022) and progressive type onset (Po0.001) were identified as independent risk factors for TTF in multivariate analyses.
Discussion
cGVHD is a systemic syndrome reflecting alloimmune and autoimmune processes, which has heterogeneous clinical manifestations and a variable prognosis. 14, 15 Several prognostic systems exist, including the Seattle criteria, 1,2 the Hopkins' risk category 4, 13 and the severity of cGVHD system. 3 In most studies looking at outcomes associated with cGVHD, 4, 13 GVHD-specific death is used as an end point, because it reflects exclusively GVHD-related mortality. The duration of systemic immunosuppressive treatment has also been used. 6 However, these end points are typically reached only after months or years of observation in clinical trials, thus prolonging the interval between the initiation of a trial and the time at which clinically meaningful data are available. The approach taken in recent colorectal cancer trials can be incorporated into studies examining cGVHD. Several clinical events that precede GVHD-specific deaths could be new candidate trial end points.
We hypothesized that the TTF could replace GVHDspecific deaths as an end point. Such a substitution is logical given that a first FU episode of cGVHD is the initial step in the pathway leading to GVHD-specific death during the clinical course of cGVHD. Since the median TTF was estimated to be a median of 73 days, if it were incorporated into clinical trials as an end point, the result could be reduced labor and financial costs for prospective clinical trials that evaluate new regimens for cGVHD or new prognostic systems.
In the present study, the correlation between TTF and GSS was significant. TTF was the only risk factor for GSS and OS in a time-dependent multivariate analysis using a Cox's proportional hazard model ( Table 3 ). The reasons for using the TTF of cGVHD as the end point were as follows: (1) the GSS for the patients without any FU was significantly different from that of the patients with one or more FU episodes ( Figure 3) ; (2) more than half the patients developed an FFU, and the median onset from transplant to episode of FFU was short (median 73 days). However, the present study has limitations due to a relatively small number of patients. In addition, the cohort was restricted to patients with cGVHD of progressive or quiescent type. Therefore, the present results regarding the association of the TTF with GSS will require further prospective validation using cohorts that include patients with de novo cGVHD using the currently available NIH diagnostic criteria for cGVHD. 5 The tapering of immunosuppressive agent dose may precipitate the development of FU during the course of cGVHD. If immunosuppressive agents are tapered rapidly, an FU episode is more likely to occur. We could not adequately evaluate the effect of the tapering pace of immunosuppressive agents on TTF, because the tapering pace in this retrospective study was uncontrolled, and depended on the various clinical situations. In addition, since patients were ascertained and categorized before establishment of the NIH consensus criteria for diagnosis and staging of cGVHD, 5 our cohort may include some patients with late-onset acute GVHD, a powerful adverse prognostic factor for GSS. 16, 17 Therefore, this limitation needs to be addressed prospectively in future trials, using more controlled tapering schedules of systemic immunosuppressive treatments.
Accordingly, the potential advantages of TTF as a surrogate for GSS, as demonstrated in the current study, include: (1) it is a strong independent predictor of GSS; (2) it correlates well with OS in patients with progressive-or quiescent-type cGVHD and (3) a shorter observation time is needed to reach this end point compared to GSS. The latter may reduce study duration and make clinically Table 3 Multivariate survival analyses to evaluate the association of time to first flare-up episode of chronic GVHD (TTF) with GVHDspecific survival and to identify the predictor of time to first flare-up of chronic GVHD Abbreviations: CI ¼ confidence interval; TTF ¼ time to first flare-up episode of GVHD. a Following clinical parameters were included in the final models for the time to the first flare-up episode of chronic GVHD: extensive chronic GVHD by Seattle's criteria, Hopkins' risk category and the severity of chronic GVHD system (with time to first flare-up episode of GVHD for GVHD-specific survival and overall survival analyses). b Following clinical parameters were included in the final models for the time to the first flare-up episode of chronic GVHD: progressive-type onset, thrombocytopenia, extensive skin involvement, poor performance status, weight loss and diarrhea at diagnosis of chronic GVHD (with time to first flare-up episode of GVHD for GVHD-specific survival and overall survival analyses).
relevant results available to clinicians in a short period of time, and may also decrease financial costs and reduce the amount of labor needed to conduct future cGVHD studies.
In conclusion, the TTF seems to correlate well with GSS and OS during the clinical course of cGVHD. Accordingly, We propose that TTF should be evaluated prospectively as an alternative end point to GSS in cGVHD trial.
